Skip to content

Study · Measured the body's own peptide · 2018

2 results

An Investigation on the Therapeutic Effect of Thymosin β4 and Its Expression Levels in Streptozotocin-Induced Diabetic Mice.

Cho KS, Kim DJ, Shim B, Kim JY, Kang JM, Park SH, Lee SH, Yang HI, Kim KS

BioMed research international27 Aug 2018Cited by 2 (Europe PMC)

PMID30225249 (opens in a new tab)PMCIDPMC6129858 (opens in a new tab)DOI10.1155/2018/3421568 (opens in a new tab)PepBankPUB-30225249
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Thymosin β4 (Tβ4) treatment was known to show the potential therapeutic effects on diabetic complications. This study was performed to determine if Tβ4 expression is changed in both serum and tissues under diabetic conditions and can be a serum biomarker. Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight. The mice were sacrificed at 16 weeks after STZ injection. Tissues and plasmas were obtained to determine the expression levels of Tβ4 using ELISA, real time RT-PCR, and immunohistochemistry. The average serum glucose level was increased to approximately 400 mg/dL beginning 2 weeks after the five injections of STZ and lasting for at least 13 weeks until sacrifice. The plasma and tissue levels of Tβ4 in the age-matched control mice were not significantly different from those of the diabetic mice. In conclusion, the Tβ4 expression level in the plasmas and tissues of diabetic mice was not affected by diabetic conditions. It indirectly suggests that the therapeutic effect of Tβ4 on diabetic complications is due to its regenerative effects on damaged tissue but not to the changed expression level of Tβ4 in plasma and tissues of diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In streptozotocin-induced diabetic mice, plasma levels of the body's own thymosin beta‑4 did not differ significantly from age-matched controls.

    In plain wordsIn diabetic mice, the body's own thymosin beta‑4 level in plasma was not significantly different from control mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changePlasma thymosin beta-4 level
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetes
    Comparator
    Age-matched control mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The plasma and tissue levels of Tβ4 in the age-matched control mice were not significantly different from those of the diabetic mice.
    2 context sentences
    Summary · context
    Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight.
    Summary · context
    Tissues and plasmas were obtained to determine the expression levels of Tβ4 using ELISA, real time RT-PCR, and immunohistochemistry.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In streptozotocin-induced diabetic mice, tissue levels of the body's own thymosin beta‑4 did not differ significantly from age-matched controls.

    In plain wordsIn diabetic mice, the body's own thymosin beta‑4 level in tissues was not significantly different from control mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeTissue thymosin beta-4 level
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetes
    Comparator
    Age-matched control mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The plasma and tissue levels of Tβ4 in the age-matched control mice were not significantly different from those of the diabetic mice.
    2 context sentences
    Summary · context
    Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight.
    Summary · context
    Tissues and plasmas were obtained to determine the expression levels of Tβ4 using ELISA, real time RT-PCR, and immunohistochemistry.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.